| Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in AK Nowak, WJ Lesterhuis, PS Kok, C Brown, BGM Hughes, DJ Karikios, ... The Lancet Oncology 21 (9), 1213-1223, 2020 | 132 | 2020 |
| Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial Y Antill, PS Kok, K Robledo, S Yip, M Cummins, D Smith, A Spurdle, ... Journal for immunotherapy of cancer 9 (6), 2021 | 79 | 2021 |
| Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601). YC Antill, PS Kok, K Robledo, E Barnes, M Friedlander, SE Baron-Hay, ... Journal of Clinical Oncology 37 (15_suppl), 5501-5501, 2019 | 62 | 2019 |
| OA08. 02 DREAM-a phase 2 trial of durvalumab with first line chemotherapy in mesothelioma: final result A Nowak, P Kok, W Lesterhuis, B Hughes, C Brown, S Kao, D Karikios, ... Journal of Thoracic Oncology 13 (10), S338-S339, 2018 | 49 | 2018 |
| Enhanced recovery after surgery for advanced ovarian cancer: a systematic review of interventions trialed K Lindemann, PS Kok, M Stockler, K Jaaback, A Brand International Journal of Gynecologic Cancer 27 (6), 2017 | 46 | 2017 |
| The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols R Mercieca-Bebber, M Friedlander, PS Kok, M Calvert, D Kyte, M Stockler, ... Quality of Life Research 25, 2457-2465, 2016 | 44 | 2016 |
| Validation of progression-free survival rate at 6 months and objective response for estimating overall survival in immune checkpoint inhibitor trials: a systematic review and … PS Kok, D Cho, WH Yoon, G Ritchie, I Marschner, S Lord, M Friedlander, ... JAMA network open 3 (9), e2011809-e2011809, 2020 | 42 | 2020 |
| A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and … R Mercieca-Bebber, M Friedlander, M Calvert, M Stockler, D Kyte, PS Kok, ... Journal of patient-reported outcomes 1, 1-10, 2017 | 34 | 2017 |
| DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results. AK Nowak, WJ Lesterhuis, BGM Hughes, C Brown, PS Kok, KJ O'Byrne, ... Journal of Clinical Oncology 36 (15_suppl), 8503-8503, 2018 | 30 | 2018 |
| Tumor response end points as surrogates for overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis PS Kok, WH Yoon, S Lord, I Marschner, M Friedlander, CK Lee JCO Precision Oncology 5, 1151-1159, 2021 | 27 | 2021 |
| PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression PS Kok, P Beale, RL O'Connell, P Grant, T Bonaventura, J Scurry, Y Antill, ... Journal of gynecologic oncology 30 (5), 2019 | 23 | 2019 |
| Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601) Y Antill, PS Kok, MR Stockler, K Robledo, S Yip, M Parry, D Smith, ... Annals of Oncology 30, ix192, 2019 | 21 | 2019 |
| Pre‐and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer A Tjokrowidjaja, SJ Lord, T John, CR Lewis, PS Kok, IC Marschner, ... Cancer 128 (8), 1574-1583, 2022 | 18 | 2022 |
| The validity of progression‐free survival 2 as a surrogate trial end point for overall survival RG Woodford, DDX Zhou, PS Kok, SJ Lord, M Friedlander, IC Marschner, ... Cancer 128 (7), 1449-1457, 2022 | 18 | 2022 |
| Enhanced recovery after surgery for suspected ovarian malignancy: a survey of perioperative practice among gynecologic oncologists in Australia and New Zealand to inform a … K Lindemann, PS Kok, M Stockler, P Sykes, A Brand International Journal of Gynecologic Cancer 27 (5), 2017 | 18 | 2017 |
| Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial PS Kok, PM Forde, B Hughes, Z Sun, C Brown, S Ramalingam, A Cook, ... BMJ open 12 (1), e057663, 2022 | 10 | 2022 |
| Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis S Thavaneswaran, PS Kok, T Price Expert Review of Anticancer Therapy 17 (10), 965-979, 2017 | 9 | 2017 |
| DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial. PM Forde, AK Nowak, PS Kok, C Brown, Z Sun, V Anagnostou, ... Journal of Clinical Oncology 39 (15_suppl), TPS8586-TPS8586, 2021 | 7 | 2021 |
| Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis PS Kok, K Lee, S Lord, JCH Yang, R Rosell, K Goto, T John, YL Wu, ... Lung Cancer 154, 113-117, 2021 | 5 | 2021 |
| NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line … P Mitchell, S Siva, PS Kok, K O'Byrne, A Yeung, A Livingstone, ... Journal of Clinical Oncology 35 (15_suppl), TPS9097-TPS9097, 2017 | 5 | 2017 |
